Karyopharm Therapeutics Inc. (KPTI) News
Filter KPTI News Items
KPTI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KPTI News Highlights
- For KPTI, its 30 day story count is now at 2.
- Over the past 5 days, the trend for KPTI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about KPTI are ASH.
Latest KPTI News From Around the Web
Below are the latest news stories about KARYOPHARM THERAPEUTICS INC that investors may wish to consider to help them evaluate KPTI as an investment opportunity.
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced long-term follow up of treatment-naïve patients with myelofibrosis (MF) who participated in the Phase 1 portion of its study evaluating once-weekly selinexor in combination with ruxolitinib (NCT04562389). The data, featured in an oral presentation at the 65th American Society of Hematology Annual Meeting and Exposition (ASH 2023), show patients treated with 60 |
Great week for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) institutional investors after losing 84% over the previous yearKey Insights Given the large stake in the stock by institutions, Karyopharm Therapeutics' stock price might be... |
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 15,700 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted as of November 30, 2023 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance wit |
Karyopharm to Participate at Upcoming Investor ConferencesKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in November: |
Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO StudyKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the presentation of updated long-term safety and efficacy data from a pre-specified exploratory subgroup analysis of the SIENDO study (NCT03555422) in patients with advanced or recurrent TP53 wild-type endometrial cancer at the International Gynecological Cancer Society (IGCS) Annual Global Meeting in Seoul, South Korea. |
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2023 Earnings Call TranscriptKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2023 Earnings Call Transcript November 2, 2023 Karyopharm Therapeutics Inc. misses on earnings expectations. Reported EPS is $-0.3 EPS, expectations were $-0.28. Operator: Good morning. My name is Guru and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics […] |
Karyopharm Therapeutics (KPTI) Q3 2023 Earnings Call TranscriptAt this time, I would like to welcome everyone to the Karyopharm Therapeutics third-quarter 2023 financial results conference call. Thank you, and thank you all for joining us on today's conference call to discuss Karyopharm's third-quarter 2023 financial results and recent company progress. This release, along with a Slide presentation that we will reference during our call today, are available on our website. |
Karyopharm Therapeutics Inc (KPTI) Reports Q3 2023 Earnings, Total Revenue of $36.0 MillionNet Product Revenue of $30.2 Million, Maintains Full Year 2023 Revenue Guidance |
Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts that include selinexor data in myelofibrosis (MF) have been selected for presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 9-12, 2023, in San Diego, CA. The data include an oral presentation featuring long-term efficacy results from the Phase 1 open-label, dose-escalation stu |
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended September 30, 2023, and highlighted select corporate milestones and progress on its key clinical development programs. |